| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
(S)-Fluoxetine hydrochloride targets the serotonin transporter (SERT) as a selective serotonin reuptake inhibitor (SSRI). As the S-enantiomer of fluoxetine, it inhibits serotonin reuptake, increasing serotonin concentration in the synaptic cleft. The compound's mechanism involves binding to SERT and blocking serotonin transport. The S-enantiomer may have different pharmacological properties compared to the racemic mixture or the R-enantiomer. It is a valuable tool for studying the stereochemical requirements for SERT inhibition and for investigating serotonin-mediated signaling.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that (S)-Fluoxetine hydrochloride is a serotonin reuptake inhibitor. As the S-enantiomer of fluoxetine, it inhibits the serotonin transporter, increasing serotonin levels in the synaptic cleft. The compound's enantiomeric purity allows for studies of stereospecific effects on SERT inhibition and serotonin signaling. In vitro characterization includes receptor binding assays to determine its affinity for SERT and functional assays to measure serotonin uptake inhibition. It is a valuable tool for studying serotonin transporter function and neurochemistry.
|
| ln Vivo |
In vivo studies of (S)-Fluoxetine hydrochloride have been conducted in the context of antidepressant research. As an SSRI, it increases serotonin levels in the synaptic cleft, producing antidepressant-like effects in animal models. The S-enantiomer may have different pharmacokinetic and pharmacodynamic properties compared to the racemic mixture or the R-enantiomer. Specific in vivo efficacy data in animal models of depression are available in the primary literature. The compound is used in research on serotonin transporter function and the mechanisms of antidepressant action.
|
| Enzyme Assay |
For serotonin transporter binding assays, membrane preparations from cells expressing recombinant SERT or from brain tissue are incubated with radiolabeled ligands (e.g., [3H]-citalopram or [3H]-paroxetine) and varying concentrations of (S)-Fluoxetine hydrochloride. Non-specific binding is determined using excess unlabeled reference compounds. Following incubation at appropriate temperature (typically 4-25°C for 60-120 minutes), bound and free radioligands are separated by rapid filtration through glass fiber filters. Filters are washed and radioactivity counted by liquid scintillation. Ki values are calculated from competition curves. For functional assays, serotonin uptake is measured using radiolabeled [3H]-5-HT.
|
| Cell Assay |
For in vitro cellular assays, cell lines expressing SERT (e.g., CHO or HEK293 cells) are cultured in appropriate media under standard conditions (37°C, 5% CO2). (S)-Fluoxetine hydrochloride is dissolved in DMSO and diluted in culture medium to desired concentrations. Cells are treated with compound for specified durations. Serotonin uptake is measured by adding radiolabeled [3H]-5-HT and quantifying intracellular radioactivity. Cell viability and cytotoxicity can be assessed using standard assays. Each concentration is tested in replicate wells with vehicle controls and positive controls (e.g., fluoxetine).
|
| Animal Protocol |
For in vivo animal studies, (S)-Fluoxetine hydrochloride is typically formulated in suitable vehicles and administered via oral gavage or intraperitoneal (i.p.) injection. Dosing regimens vary by study objective. For depression models (e.g., forced swim test, tail suspension test), animals are treated with compound and behavioral responses are recorded. For pharmacokinetic studies, blood and brain tissue samples are collected at predetermined time points. All procedures must follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (S)-Fluoxetine hydrochloride are similar to those of fluoxetine. The compound has a molecular weight of 345.79 and formula C17H19ClF3NO. CAS number: 114247-06-2. Purity: ≥98% (HPLC). Storage: typically at -20°C for powder; in solvent at -80°C. Solubility: soluble in DMSO and other organic solvents. As an SSRI, it has good oral bioavailability and blood-brain barrier penetration. Specific pharmacokinetic parameters such as half-life, clearance, and bioavailability are reported for fluoxetine in the primary literature.
|
| Toxicity/Toxicokinetics |
According to available safety information, (S)-Fluoxetine hydrochloride is intended for research purposes only and is not for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available.
|
| References | |
| Additional Infomation |
(S)-Fluoxetine hydrochloride is the hydrochloride salt prepared by reacting (S)-fluoxetine with an equivalent amount of hydrochloric acid. It is an antidepressant and a serotonin reuptake inhibitor. It contains (S)-fluoxetine (1+) and is the enantiomer of (R)-fluoxetine hydrochloride.
(S)-Fluoxetine hydrochloride is the S-enantiomer of fluoxetine, a selective serotonin reuptake inhibitor (SSRI). It is an antidepressant and serotonin reuptake inhibitor. It is used in research on serotonin transporter function and neurochemistry. It has a molecular weight of 345.79 and formula C17H19ClF3NO. It is for research use only with no regulatory approvals reported as a single enantiomer therapeutic agent. |
| Molecular Formula |
C17H19CLF3NO
|
|---|---|
| Molecular Weight |
345.79
|
| Exact Mass |
345.111
|
| CAS # |
114247-06-2
|
| Related CAS # |
Fluoxetine;54910-89-3;Fluoxetine hydrochloride;56296-78-7;(R)-Fluoxetine hydrochloride;114247-09-5
|
| PubChem CID |
9884593
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
395.1ºC at 760 mmHg
|
| Flash Point |
192.8ºC
|
| Vapour Pressure |
1.88E-06mmHg at 25°C
|
| LogP |
5.627
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
308
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CNCC[C@@H](C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl
|
| InChi Key |
GIYXAJPCNFJEHY-NTISSMGPSA-N
|
| InChi Code |
InChI=1S/C17H18F3NO.ClH/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20;/h2-10,16,21H,11-12H2,1H3;1H/t16-;/m0./s1
|
| Chemical Name |
(3S)-N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8919 mL | 14.4596 mL | 28.9193 mL | |
| 5 mM | 0.5784 mL | 2.8919 mL | 5.7839 mL | |
| 10 mM | 0.2892 mL | 1.4460 mL | 2.8919 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
